LOGIN
ID
PW
MemberShip
2025-02-07 04:11
All News
Policy
Company
Product
Opinion
InterView
°Ë»ö
Dailypharm Live Search
Close
Company
Epkinly may be prescribed in general hospitals in KOR
by
Eo, Yun-Ho
Jan 31, 2025 05:56am
Epkinly, an innovative bispecific antibody drug that binds to T cells, may now be prescribed in general hospitals in Korea. According to industry sources, AbbVie Korea¡¯s Epstein-Barr virus (EBV)-associated diffuse large B-cell lymphoma (DLBCL) treatment Epkinly (epcoritamab) has recently passed the drug committee (DC) review of Asan Medi
Company
'Latuda,' the new schizophrenia drug, can be prescribed
by
Eo, Yun-Ho
Jan 31, 2025 05:56am
'Latuda,' a treatment for schizophrenia, becomes available for prescription at general hospitals. According to industry sources, Bukwang Pharmaceutical's Latuda (lurasidone) has passed the drug committees of tertiary general hospitals, including Samsung Medical Center, Seoul National University Hospital, and Severance Hospital in Sinchon
Company
KDA ¡®Concern on use of SGLT2 inhibitors for weight loss'
by
Whang, byung-woo
Jan 31, 2025 05:56am
As interest in weight loss has increased with the advent of new GLP-1 analogs, experts have warned of the risk of overuse of SGLT2 inhibitors for weight loss or cosmetic purposes. The Korean Diabetes Association has recently issued a series of statements on the safe use of SGLT2 inhibitors for both experts and the general public. As the nu
Company
3 variables affecting the growth of 'Entresto'
by
Kim, Jin-Gu
Jan 31, 2025 05:55am
Novartis' chronic heart failure treatment 'Entresto (sacubitril/valsartan)' has maintained high growth, with prescription sales exceeding KRW 70 billion last year. Analysis suggests that expanded indications in 2022 and 2023 have led to skyrocketed growth. However, it is unknown whether this growth rate will continue this year. Numerous
Company
Companies produced KRW 66.7B finished drugs a year
by
Chon, Seung-Hyun
Jan 24, 2025 05:52am
The average production performance of pharmaceutical companies has been gradually increasing. As the scale of the pharmaceutical industry grew, the average production value of both finished drugs and raw materials also continued to grow. For both finished drugs and raw materials, the share of small companies with annual production of less than K
Company
Will long-acting HIV treatment be included in the reimb list
by
Eo, Yun-Ho
Jan 24, 2025 05:52am
The long-acting HIV treatment 'vocabria+rekambys' gets attention whether it will be included in the National Health Insurance reimbursement list, two years after receiving approval in South Korea. According to industry sources, GSK Korea and Janssen Korea have recently entered drug price negotiations for their new HIV drugs, vocabria (cab
InterView
Approval called for drug switching in atopic dermatitis
by
Whang, byung-woo
Jan 24, 2025 05:51am
Atopic dermatitis treatment settings are changing quickly. New treatment options are available as new drugs with fewer side effects and superior treatment effectiveness than existing therapies emerge. There is a growing interest in how atopic dermatitis can be treated rather than just treating it, as changes have been brought to the treatment
Policy
'Lixiana' patent expires next year, good news for
by
Lee, Hye-Kyung
Jan 24, 2025 05:51am
As the patent of 'Lixiana (edoxaban),' a Direct Oral Anti-Coagulant (DOAC), is set to expire, generic companies are entering the competition. On January 21, the Ministry of Food and Drug Satefy (MFDS) approved bioequivalence tests, which are open-label, randomized, two groups, single time-point, cross-over Phase 2 trials involving healthy
Policy
Hokunalin Patch has been removed from Korea¡¯s reimbursement
by
Lee, Tak-Sun
Jan 24, 2025 05:51am
Hokunalin Patch, asthma and bronchitis deodorant based on tulobuterol, will be removed from the reimbursement list. The move was made upon the expiry of the item¡¯s marketing authorization last month. As a result, only domestic generic versions of the drug are available in South Korea. According to industry sources on Jan. 22, Abbott'
Policy
Govt plans to expand CDMO capacity by 2.5 times
by
Lee, Hye-Kyung
Jan 24, 2025 05:51am
The government plans to expand Korea¡¯s CDMO manufacturing capacity 2.5 times by 2032 to become the No. 1 global CDMO by 2032. It will also support domestic companies with a 'megafund' by expanding the size of the K-Bio-Vaccine Fund, currently at KRW 600 billion, to over KRW 1 trillion. The government launched the National Bio Commission i
1
2
3
4
5
6
7
8
9
10
>